EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.

Activating epidermal growth factor receptor (EGFR) mutations are recognized biomarkers for patients with metastatic non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs can also have activity against NSCLC without EGFR mutations, requiring the identificat...

Full description

Saved in:
Bibliographic Details
Main Authors: Florent Baty, Sacha Rothschild, Martin Früh, Daniel Betticher, Cornelia Dröge, Richard Cathomas, Daniel Rauch, Oliver Gautschi, Lukas Bubendorf, Susanne Crowe, Francesco Zappa, Miklos Pless, Martin Brutsche, Swiss Group for Clinical Cancer Research
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2013
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/df9c71b1c1b54bdabc04d593f01a7ee1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/df9c71b1c1b54bdabc04d593f01a7ee1

Similar Items